Mello 2019

RNS Number : 5235Y

Creo Medical Group PLC

10 May 2019

 

Creo Medical Group plc

("Creo" or the "Company")

Mello 2019

Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy, announces it will be exhibiting at Mello 2019 on Thursday 16 May at the Clayton Hotel Chiswick, London.

Members of Creo's management team will be at a stand in the Exhibitor Room throughout the day and Chris Hancock, CTO, will be presenting at 9.15am in the PI World Room.

For further information, please visit the event website at: https://melloevents.com/event/

The presentation will be available on the Company website shortly after the event here:

http://investors.creomedical.com/investors/reports-and-presentations/2019 

If you are interested in attending the event and would like information on how to register, please contact Walbrook PR at [e-mail]

No new material information will be disclosed at the event.

Creo Medical Group plc
Richard Rees (CFO)	[phone]
Cenkos Securities	[phone]
Stephen Keys / Mark Connelly (NOMAD)
Michael Johnson / Russell Kerr (Sales)
Walbrook PR Ltd	Tel: [phone] or [e-mail]
Paul McManus	Mob: [phone]
Helen Cresswell	Mob: [phone]

About Creo Medical

Creo Medical, founded in 2003, is a medical device company focused on the development and commercialisation of minimally invasive surgical devices, by bringing advanced energy to endoscopy. Creo's mission is to improve patient outcomes by applying microwave and RF energy to surgical endoscopy. Creo has developed CROMA, an electrosurgical advanced energy platform that combines bipolar radio frequency energy (for precise localised cutting) and microwave energy (for controlled coagulation). This technology provides clinicians with flexible, accurate and controlled surgical solutions.

Creo's strategy is to bring its CROMA Advanced Energy platform to market through a suite of medical devices which Creo has designed, initially for the emerging field of GI therapeutic endoscopy, an area with high unmet needs.  Creo intends to further develop the CROMA Advanced Energy platform for use on flexible and rigid endoscopic platforms for precise resection, dissection, haemostasis and ablation. Creo believes its technology can impact the landscape of surgery and endoscopy by providing a safer, less invasive and more cost-efficient option of treatment.

For more information about Creo Medical please see our website, investors.creomedical.com

 

END

 

 

NRAUGUGUAUPBGUB